Apogem Capital’s Haemonetics HAE Stock Holding History

Apogem Capital’s Portfolio HAE Stock Details HAE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-2,973	Closed	-$210K	–	186
2021 Q3	$210K	Sell	2,973 -7,216	-71%	-$455K	0.13%	171
2021 Q2	$679K	Buy	+10,189	New	+$721K	0.43%	88

Other funds holding HAE

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

LCP

LGT Capital Partners Pfaeffikon, Switzerland $1.88B AUM 20.37% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Apogem Capital's HAE Position: Q4 2021 in Review

Apogem Capital sold out of Haemonetics (HAE) in Q4 2021, closing a stake of 2,973 shares — an estimated $210K sold.

Apogem Capital first reported a position in HAE in Q2 2021 and held it in 2 quarters. The position peaked at $679K in Q2 2021. 257 funds tracked by Wall St. Rank hold HAE as of Q4 2021.

Apogem Capital reported no remaining Haemonetics position as of Q4 2021 after selling out during the quarter.
Apogem Capital sold 2,973 Haemonetics shares in Q4 2021, an estimated $210K.
Apogem Capital first reported a position in Haemonetics in Q2 2021 and held it in 2 quarters.
Apogem Capital's Haemonetics position peaked at $679K in Q2 2021.
257 funds tracked by Wall St. Rank held Haemonetics as of Q4 2021.

Based on Apogem Capital's 13F filing for Q4 2021, filed 14 Feb 2022.